{"id":"W2489933219","doi":"10.1200/jco.2012.30.4_suppl.386","title":"Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory <i>K-RAS </i>wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Chemotherapy; Gastroenterology; Clinical endpoint; Placebo; Population; Progression-free survival; Colorectal cancer; Refractory (planetary science); Bevacizumab; Cetuximab; Surgery; Oncology; Urology; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001706722,0.002293953,0.0022476,0.0004087357,0.0004512721,0.001100417,0.001106508,0.002214087,0.009679961],"category_scores_gemma":[0.001508867,0.0008667677,0.001073867,0.0004595838,0.001391214,0.001108647,0.0005140337,0.003510768,0.001929316],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001162184,"about_ca_system_score_gemma":0.001607156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001980369,"about_ca_topic_score_gemma":0.004819204,"domain_scores_codex":[0.999594,0.0002145182,0.00001673565,0.00006975787,0.00002828897,0.00007676939],"domain_scores_gemma":[0.9992363,0.0001392112,0.0001680752,0.00005059441,0.00004244409,0.0003633555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9804621,0.006005201,0.0004001988,0.0002860375,0.0002783254,0.00004470375,0.00003976875,0.0003536115,0.002102435,0.0001381927,0.001973619,0.007915908],"study_design_scores_gemma":[0.9680369,0.02988981,0.000736249,0.00001659551,0.0001137477,0.00002612855,0.00001174595,0.0002682636,0.0001830603,0.0001077163,0.0006023249,0.00000747554],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731578,0.003695066,0.0009037043,0.001969573,0.001024809,0.01029903,0.003307717,0.0003085391,0.005333878],"genre_scores_gemma":[0.9641331,0.002628621,0.002333736,0.003115081,0.0006430518,0.01245948,0.003836313,0.00005810089,0.0107925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009679961,"threshold_uncertainty_score":0.03238273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1603552028936808,"score_gpt":0.491825238937917,"score_spread":0.3314700360442362,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}